Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in China / NCT05325216
Starting soon Not applicable

Urinary Continence of Female POPRC and OIN

NCT05325216 · tracked via the Priya Life Science China tracker
Sponsor
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase
Not applicable
Started
2022-04
Last updated
2022-04-13

Condition(s) studied

Urinary Bladder NeoplasmsWomanSexual Dysfunction, PhysiologicalTreatment OutcomeUrinary Incontinence

Investigational drug(s) / intervention(s)

POPRC+OINSRC+OIN

POPRC+OIN: Pelvic-organ preserving radical cystectomy with orthotopic ileal neobladder

SRC+OIN: Standard radical cystectomy with orthotopic ileal neobladder

Study summary

To compare the urinary continence rate and long-term oncological outcomes of pelvic-organ preserving radical cystectomy (POPRC) with orthotopic ileal neobladder (OIN) versus standard radical cystectomy(SRC) with OIN.

Eligibility

Sex
FEMALE
Min age
55 Years
Max age
75 Years
Healthy volunteers
No
Inclusion Criteria: 1. Female patients aged between 55-75. 2. Patients those who are diagnosed with organ-confined urothelial carcinoma（\<pT3） 3. Patients those who are capable for radical cystectomy with orthotopic ileal neobladder. 4. ECOG score between 0-2; 5. Normal renal function; 6. Patients those who volunteer to participate in this study and sign the informed consents. 7. Patients those who are able to cooperate in the study. Exclusion Criteria: 1. Absence of tumour in bladder neck or urethra; 2. Patients thsoe who are diagnosed distant metastasis before surgery. 3. Previous history of malignancy of pelvic organs or surgical resection of pelvic organs; 4. Patients those who are diagnosed with other malignancies.; 5. Patients those who had received pelvic radiotherapy or major pelvic operation. 6. Pregnancy status; 7. Any other conditions that the researcher considers to be excluded from this study

Primary outcome measure(s)

  • day-time and night-time continence rate — 6 months
    We will use pad-test to evaluate the urinary continence for patients

Trial sites (1)

FacilityCityRegionStatus
Sun Yat-Sen Memorial Hospital Guangzhou Guangdong

More Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University trials in China

Efficacy and Safety of rTMS Combined With HA in the Treatment of Cognitive Decline in Aged Related Hearing Loss Recruiting
Fulvestrant or Capecitabine Combined With Pyrotinib in HR+/HER2+ Metastatic Breast Cancer Recruiting
Fluorizoparib Plus Apatinib Versus Chemotherapy in HRD-positive, HER2-negative Advanced Breast Cancer Active, not recruiting
Research on the Development and Validation of Personalized Exercise Prescription System for Breast Cancer Patients Based on Large Language Models Starting soon
Neoadjuvant Toripalimab or Toripalimab in Combination With Carboplatin and Nab-paclitaxel in Untreated HNSCC (HNSCC-002) Recruiting

Other trials for the same condition

FAPI and FDG PET/MRI in Diagnosis and Therapy Prediction of Bladder Cancer Recruiting
99Tc-MDP Treatment for Knee Osteoarthritis Recruiting
An International Multicenter Clinical Study on Application of UroMed AI Doctor Based on Large Language Models Starting soon
A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract Recruiting
A Study of TAR-200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle-invasive Bladder Cancer (MIBC) of the Bladder Active, not recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05325216 on ClinicalTrials.gov ↗ ← All trials in China